Treatment for Multiple Myeloma | XPOVIO® (selinexor) HCP

With XPOVIO you can:

Icon representing a different treatment class

Introduce a different treatment class¹

Deliver proven efficacy^† in combination with Vd, with efficacy observed across a variety of patient subgroups^1,2

Icon representing oral, once-weekly therapy

Provide oral, once-weekly tablets that are readily accessible and can be taken at home^1,3*

Administer treatment and monitor patients without required hospitalization¹

XVd is an NCCN Category 1 regimen in early RRMM⁴

Oral, once-weekly selinexor (XPOVIO) in combination with bortezomib and dexamethasone (XVd) is recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as an NCCN Category 1^‡ therapeutic option in RRMM after 1 to 3 prior therapies.

*XPOVIO® (selinexor) is a prescription medicine approved in combination with subcutaneous bortezomib injection and oral dexamethasone in 2L+ RRMM.

^†XVd vs Vd trial: Phase 3, global, open-label study of adult patients with MM who received 1 to 3 prior therapies that compared XVd with Vd in 402 patients randomized into 2 study arms. 195 patients were treated with once-weekly XPOVIO and bortezomib and twice-weekly dexamethasone. 207 patients were treated with twice-weekly bortezomib and 4-times-weekly dexamethasone. The primary endpoint was PFS, and select secondary endpoints included ORR and DOR. The XVd mPFS of the ITT population was 13.9 months vs a Vd mPFS of 9.5 months (HR: 0.70 [95% CI: 0.53, 0.93], P=0.0075).¹

^‡Category 1: Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.

Understand the Need

Unmet Need

Patients across the RRMM treatment landscape need different drug classes.^5-7

Examine the Data

XVd Trial Results

See the PFS benefit of XPOVIO + Vd compared to Vd, including how certain subgroups responded.^1,2

Explore Patient Profiles

Patient Profiles

Explore how XPOVIO + Vd can help you meet your patients where they are in their RRMM journey.¹

Discover Support

Patient Support

Enroll your patients in KaryForward®, the support program dedicated to helping them start and stay on XPOVIO + Vd.

Abbreviations: AR, adverse reaction; CI, confidence interval; DOR, duration of response; HR, hazard ratio; ITT, intent-to-treat; MM, multiple myeloma; mPFS, median progression-free survival; ORR, overall response rate; PFS, progression-free survival; RRMM, relapsed or refractory multiple myeloma; Vd, bortezomib and dexamethasone; XVd, selinexor, bortezomib, and dexamethasone.

NCCN, National Comprehensive Cancer Network®.

References: 1. XPOVIO (selinexor) [prescribing information]. Newton, MA: Karyopharm Therapeutics, Inc. 2. Data on file. Karyopharm Therapeutics, Inc. 2021 [1]. 3. Data on file. Karyopharm Therapeutics, Inc. 2023 [2]. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed June 3, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. 5. Mateos MV, Weisel K, DeStefano V, et al. Leukemia. 2022;36(5):1371-1376. doi:10.1038/s41375-022-01531-2 6. Lesokhin AM, Tomasson MH, Arnulf B, et al. Nat Med. 2023;29(9):2259-2267. doi:10.1038/s41591-023-02528-9 7. Gandhi UH, Cornell RF, Lakshman A, et al. Leukemia. 2019;33(9):2266-2275. doi:10.1038/s41375-019-0435-7

INDICATION

XPOVIO® (selinexor) is a prescription medicine approved in combination with bortezomib and dexamethasone (XVd) to treat adult patients with multiple myeloma who have received at least one prior therapy.

IMPORTANT SAFETY INFORMATION

Thrombocytopenia: XPOVIO can cause life-threatening thrombocytopenia, potentially leading to hemorrhage. Thrombocytopenia was reported in patients with multiple myeloma.

Thrombocytopenia is the leading cause of dosage modifications. Monitor platelet counts at baseline and throughout treatment. Monitor more frequently during the first 3 months of treatment. Monitor patients for signs and symptoms of bleeding. Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.

Neutropenia: XPOVIO can cause life-threatening neutropenia, potentially increasing the risk of infection.

Monitor more frequently during the first 3 months of treatment. Consider supportive measures, including antimicrobials and growth factors (e.g., G-CSF). Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.

Gastrointestinal Toxicity: XPOVIO can cause severe gastrointestinal toxicities in patients.

Nausea/Vomiting/Diarrhea: Provide prophylactic antiemetics or treatment as needed.

Anorexia/Weight Loss: Monitor weight, nutritional status, and volume status at baseline and throughout treatment and provide nutritional support, fluids, and electrolyte repletion as clinically indicated.

Hyponatremia: XPOVIO can cause severe or life-threatening hyponatremia.

Monitor sodium level at baseline and throughout treatment.

Serious Infection: XPOVIO can cause serious and fatal infections. Atypical infections reported after taking XPOVIO include, but are not limited to, fungal pneumonia and herpesvirus infection.

Neurological Toxicity: XPOVIO can cause life-threatening neurological toxicities.

Coadministration of XPOVIO with other products that cause dizziness or mental status changes may increase the risk of neurological toxicity.

Advise patients to refrain from driving and engaging in hazardous occupations or activities, until the neurological toxicity fully resolves. Institute fall precautions as appropriate.

Embryo-Fetal Toxicity: XPOVIO can cause fetal harm when administered to a pregnant woman.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with a female partner of reproductive potential to use effective contraception during treatment with XPOVIO and for 1 week after the last dose.

Cataracts: New onset or exacerbation of cataract has occurred during treatment with XPOVIO. The incidence of new onset or worsening cataract requiring clinical intervention was reported.

ADVERSE REACTIONS

The most common adverse reactions (ARs) (≥20%) in patients with multiple myeloma who received XVd were fatigue, nausea, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, decreased weight, cataract, and vomiting.

Grade 3-4 laboratory abnormalities (≥10%) were thrombocytopenia, lymphopenia, hypophosphatemia, anemia, hyponatremia and neutropenia.

Fatal ARs occurred in 6% of patients within 30 days of last treatment. Serious ARs occurred in 52% of patients. Treatment discontinuation rate due to ARs was 19%. The most frequent ARs requiring permanent discontinuation in >2% of patients included fatigue, nausea, thrombocytopenia, decreased appetite, peripheral neuropathy and vomiting. Adverse reactions led to XPOVIO dose interruption in 83% of patients and dose reduction in 64% of patients.

USE IN SPECIFIC POPULATIONS

No overall difference in effectiveness of XPOVIO was observed in patients >65 years old when compared with younger patients. Patients ≥65 years old had a higher incidence of discontinuation due to an adverse reaction (AR) and a higher incidence of serious ARs than younger patients.

The effect of end-stage renal disease (CL_CR <15 mL/min) or hemodialysis on XPOVIO pharmacokinetics is unknown.

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Karyopharm Therapeutics Inc. at 1-888-209-9326 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

In RRMM, meet your patients where they are with a... TREATMENT THAT FITS1*